Development of the B cell cancer vaccine HER-vaxx for the treatment of her-2 expressing cancers.
- DOI
- 10.3389/fonc.2022.939356
- Published
- 2022
- Container
- Frontiers in oncology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.3389/fonc.2022.939356,
title = {Development of the B cell cancer vaccine HER-vaxx for the treatment of her-2 expressing cancers.},
author = {Ede NJ and Good AJ and Tobias J and Garner-Spitzer E and Zielinski CC and Wiedermann U},
year = {2022},
journal = {Frontiers in oncology},
doi = {10.3389/fonc.2022.939356},
url = {https://doi.org/10.3389/fonc.2022.939356}
}RIS
TY - JOUR TI - Development of the B cell cancer vaccine HER-vaxx for the treatment of her-2 expressing cancers. AU - Ede NJ AU - Good AJ AU - Tobias J AU - Garner-Spitzer E AU - Zielinski CC AU - Wiedermann U PY - 2022 JO - Frontiers in oncology DO - 10.3389/fonc.2022.939356 UR - https://doi.org/10.3389/fonc.2022.939356 ER -
APA
NJ, E., AJ, G., J, T., E, G., CC, Z., & U, W. (2022). Development of the B cell cancer vaccine HER-vaxx for the treatment of her-2 expressing cancers.. Frontiers in oncology. https://doi.org/10.3389/fonc.2022.939356
Source records
- pubmed · retrieved 2026-09-27T10:43:42.090Z